Subject category:
Strategy and General Management
Published by:
International Institute for Management Development (IMD)
Version: 03.06.2016
Length: 13 pages
Data source: Published sources
Share a link:
https://casecent.re/p/140355
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This two-part case series examines the strategic positioning of Novartis - a leading Swiss multinational - in the life sciences industry during the last decade. Case A provides an introduction to Novartis and the major decisions taken by its longest-serving CEO, Daniel Vasella. It also offers an overview of the industry's challenges in the period following the financial crisis of 2008/2009, and a profile of some of its major players. It concludes by placing the spotlight on the dilemma faced by the company's newly appointed CEO Joe Jimenez: Should he pursue the strategy of his predecessor or not? This case can be used as a standalone item.
Location:
Industry:
Size:
USD58.6 billion in 2011
Other setting(s):
1996-2016
About
Abstract
This two-part case series examines the strategic positioning of Novartis - a leading Swiss multinational - in the life sciences industry during the last decade. Case A provides an introduction to Novartis and the major decisions taken by its longest-serving CEO, Daniel Vasella. It also offers an overview of the industry's challenges in the period following the financial crisis of 2008/2009, and a profile of some of its major players. It concludes by placing the spotlight on the dilemma faced by the company's newly appointed CEO Joe Jimenez: Should he pursue the strategy of his predecessor or not? This case can be used as a standalone item.
Settings
Location:
Industry:
Size:
USD58.6 billion in 2011
Other setting(s):
1996-2016